We describe the construction and evaluation of a recombinant hepatitis B surface antigen (HBsAg)-vectored DNA vaccine encoding the E7 and E6 tumor-associated oncoproteins of human papillomavirus (HPV) type 16. We show the induction of effector and memory cytotoxic T lymphocyte responses to E7 and E6 class I-restricted epitopes after a single immunization, which were associated with tumor prevention and therapy. The findings vindicate the use of a HBsAg-based DNA vaccine as a vehicle to elicit responses to co-encoded tumor antigens, and have specific implications for the development of a therapeutic vaccine for HPV-associated squamous carcinomas.
Introduction
Human papillomaviruses (HPVs) are associated with a number of squamous cell cancers. HPV is detected in ca 80% of cervical carcinomas, particularly the 'high-risk' genotypes HPV 16 and 18. HPV E7 and E6 oncoproteins are responsible for transforming cervical epithelial cells principally by abrogating the cell-cycle control functions of cellular retinoblastoma protein and p53, respectively. 1, 2 The E7 and E6 proteins must persist for cells to remain transformed, 3 and so they provide tumor-associated antigen targets for immunotherapeutic strategies designed to eradicate HPV-associated neoplasia. CD8 þ cytotoxic T lymphocytes (CTLs) are crucial components of protective immune responses to both murine 4 and human 5 tumors. CTLs kill tumor cells displaying epitopes derived from tumor-associated antigens arrayed on the tumor cell surface in conjunction with major histocompatibility complex molecules. Using a number of experimental murine vaccines including peptides, 6 plasmid DNA, 7 viral vectors 8 recombinant fusion proteins 9 and chimeric virus-like particles (VLPs), 10 the CTL response to E7 and E6 proteins has been shown to be an important determinant of HPV-associated disease outcome. The outcome of E7-directed human clinical trials using peptide 11 or recombinant vaccinia viruses expressing E7 and E6 12 as immunogens has been equivocal, although CTL generation was observed in some patients. Although a number of experimental therapeutic vaccines for HPV-associated malignancy has been reported in animal models, (for example, Chu et al., 9 Peng et al., 13 Herd et al., 14 Echchannaoui et al., 15 Daftarian et al., 16 Chen et al. 17 ), it is clear that potent strategies readily applicable to humans for inducing CTLs and for priming and boosting anti-tumor responses are necessary, and yet to be developed.
The small envelope protein of hepatitis B surface antigen (HBsAg) comprises the globally licensed human vaccine for hepatitis B infection, with a ca 25-year history of safety and efficacy in millions of recipients. When administered either as VLPs or as DNA, HBsAg elicits powerful CTL and B-cell responses, 18, 19 inviting it's usage as a vector to deliver immunogenic moieties from other pathogens and tumors. Using DNA as immunogen, CTL induction by intracellular translated HBsAg protein occurs through the 'classical' endogenous antigen presentation pathway, and may occur through the 'alternative' exogenous pathway through secreted HBsAg protein or VLPs. 19, 20 HBsAg may complement the way that DNA vaccines are presented to the immune system by some intrinsic adjuvant-like characteristic, or by providing potent T-help. We have previously highlighted the enormous potential of HBsAg as a generic vaccine framework for inducing potent protective immunity, 21 and it is clear that this potential is only just being realized.
DNA vaccines hold considerable promise as a modality for prevention and treatment for tumors expressing tumor-associated antigens and which are susceptible to a cell-mediated response for their resolution. 22 A number of DNA vaccine enhancing strategies (for example, primeboost regimens, targeting the DNA to dendritic cells, co-administration of cytokines) are emerging to dispel earlier difficulties of translating promising results in mice to humans, and a number of clinical trials are underway (for example, Rice et al. 23 ).The capacity of HBsAg to augment DNA vaccines may also prove to be one such strategy.
In this study, we describe the application of a single, low-dose, codon-optimized recombinant HBsAg DNA encoding HPV E7 and E6 tumor-associated proteins, as a vaccine to elicit long-lived CTL responses, which protect against the growth of HPV-associated tumor. The results underscore the efficacy of HBsAg as a DNA vaccine delivery platform. They also have implications for therapeutic human vaccine for HPV-associated cervical, and other, squamous carcinomas.
Materials and methods

pE7HBE6
Oligonucleotides (Geneworks Pty Ltd, Hindmarsh, Australia) were extended and amplified by splice overlap extension-PCR to make seven overlapping double stranded DNA fragments, subsequently amplified to three fragments, which were annealed to make full-length E7HBsAgE6 flanked by DNA encoding hexahis and FLAG tags at the 5 0 -and 3 0 -ends, respectively. Fragments were extended to between 250 and 320 bp by the inclusion of 6-8 overlapping oligonucleotides in a single splice overlap extension-PCR reaction, using either PrimeStarHS DNA Polymerase (Takara, Shiga, Japan). A PCR cycle including a thermal ramp to cool from denaturing temperature to annealing temperature was required to minimize mutation: 98 1C for 15 s, a thermal ramp (1 1C s -1 ) to 68 1C, which was held for 30 s, 25 cycles and including a 4 1C-holding step. The PCR products were sequenced for authenticity. Mutations were eliminated by restriction enzyme digest and QuikChange XL site directed mutagenesis, as per manufacturer's instructions (Stratagene, Macquarie Park, Australia), followed by sequencing for confirmation of authenticity. E7HBsAgE6 was inserted into pcDNA3 to create pE7-HBsAg-E6 DNA vaccine (denoted pE7HBE6). 24, 25 Peptides EVY(E6) and QAEPDRAHY-NIVTFCCKCD, denoted 'RAH(E7)', were synthesized with free ends, analyzed by high-performance liquid chromatography and mass spectrometry (Genscript Pty Ltd, Piscataway, NJ), dissolved in 10% dimethylsulphoxide, and diluted into tissue culture medium or used for peptide vaccination, as required.
Mice
Female H-2 b mice were housed under specific pathogenfree conditions, and used at 7-15 weeks of age.
Immunization and restimulation of splenocytes
Mice were immunized intradermally in the ear with purified plasmid DNA prepared by EndoFree Plasmid Giga Kit (Qiagen, Doncaster, Australia). Two weeks after immunization, spleens were removed and splenocytes were restimulated in vitro for 6 days as described 7 with 1 mg ml -1 cognate peptide. For peptide immunizations, mice were immunized subcutaneously at the tail base with 50-100 mg peptide þ 0.25 mg tetanus toxoid as a source of T-helper epitopes þ 10 mg Quil A adjuvant. 7 After 8 days, spleens were harvested and splenocytes were restimulated as above. Cells EL4.A2 cells are susceptible to specific CTL lysis through the H-2 b restriction pathway. C2 cells were derived by transfecting EL4 cells with pJ4OE7, and are susceptible to CTL lysis directed to E7.
7 Cells were maintained as described. 7 TC-1 is a tumor cell line derived from primary epithelial cells of C57BL/6 mice by co-transfection with HPV 16 E6, E7 and Ha ras oncogenes. 8 TC-1 cells were prepared for injection in Hank's balance salt solution.
Murine IFN-g ELISPOT assay Epitope-specific gamma interferon (IFN-g)-secreting spleen cells were enumerated ex vivo by an enzyme-linked immunospot (ELISPOT) assay with CD8 þ T-cell epitope peptides, essentially as described. 7 IFN-g spots were counted using an AID ELISPOT reader system. Results were calculated as IFN-g-positive cells per 10 6 spleen cells±s.e.m.
51 Chromium-release CTL assay CTL assays were conducted as previously described. 7 In summary, target cells (10 4 per well) sensitized at 37 1C for 1 h with 1 mg ml -1 cognate or irrelevant peptide, or CD4 þ cell depletion Mice were injected intraperitoneally with 200 ml of 50:50 mix of GK1.5 ascitic fluid:phosphate-buffered saline six times at 2-to 3-day intervals, commencing 1 day after immunization. Confirmation of CD4 þ cells depletion was monitored by fluorescence-activated cell sorting analysis of peripheral blood mononuclear cells, 3 days after final administration of GK1.5 using fluorescein isothiocyanate-labelled anti-mouse CD4 antibody (Molecular Biosciences, Kensington, Australia). Nondepleted mice were injected with 200 ml of phosphatebuffered saline using the same regimen.
Tumor protection assays
Prophylaxis for subcutaneous tumor. Groups of H-2 b mice (seven per group) were immunized once with 100 mg pE7HBE6 or pHB w/t intradermally CTL responses to tumor epitopes RAH(E7) and EVY(E6) were confirmed in two representative mice per group on day 14 after immunization by IFN-g ELISPOT conducted on ex vivo splenocytes. The following day, the remaining five mice per group were injected subcutaneously on the flank with TC-1 cells. (The tumor dose was pre-determined by titration experiments to discern a dose of 2 Â 10 5 giving rise to tumor in 80-100% of unimmunized mice). Mice were monitored for incidence of tumor with time. Data are presented as Kaplan-Meier tumor incidence curves of % tumor-free mice at given time points after tumor injection. Therapy for subcutaneous tumor: H-2 b mice (seven per group) were injected subcutaneously with 5 Â 10 5 TC-1 cells. Commencing 11 days later, the mice were immunized intradermally five times at 3-day intervals with 100 mg pE7HBE6 or pHB. Tumor growth was monitored as % survival and by caliper measurement of individual tumors. Therapy for lung metastasis: H-2 b mice (five per group) were injected intravenously (tail vein) with 1 Â 10 5 TC-1 cells in 100 ml Hank's balance salt solution. The mice were immunized twice 3 and 10 days later with 100 mg pE7HBE6 or pHB w/t or 50 mg each of pE7HBE6 ko plus pE7 ko HBE6. Lungs were excised 18 days after the second immunization, fixed in neutral formalin, paraffinembedded, sectioned (up to 11 sections spread evenly throughout lung) and stained with hematoxylin and eosin. Tumor incidence was recorded microscopically by a clinical anatomical pathologist unaware of experimental design.
Statistics
Experimental values were compared for significant difference using Student's t-test. Kaplan-Meier tumor incidence curves were compared using the log-rank statistic.
Results
pE7HBsAgE6
A recombinant HBsAg fusion complementary DNA (E7HBE6) was designed to encode the HPV16 E7 protein appended at the N 0 -terminus, and the HPV16 E6 protein appended at the C 0 -terminus ( Figure 1a ) and cloned into the mammalian expression plasmid pcDNA3. The known oncogenicity of the HPV E7 and E6 proteins was eliminated by replacing critical cysteine residues with glycine residues. 26, 27 The entire construct was codon optimized for maximized expression in mammalian cells. Expression of E7HBE6 protein was confirmed by western blotting in Sf9 cells infected with a recombinant baculovirus expressing the E7HBE6 gene (Figures 1b-d ). We asked whether immunization with pE7HBE6 would induce CTL memory, which could be recalled in mice at later time points after immunization. Restimulated splenocytes from mice harvested up to at least 23 weeks (last time point examined) after a single immunization with pE7HBE6 killed target cells presenting RAH(E7) peptide (Figure 2e) . Similarly, restimulated splenocytes harvested up to 6 weeks after immunization killed target cells presenting the EVY(E6) peptide (Figure 2e) . Together, the above data indicate that immunization with rHBsAg plasmid DNA encoding E7 and E6 tumor antigens primes for IFN-g-associated effector and memory CTL responses, which are cytotoxic for target cells expressing E7 and E6 CTL epitopes.
Dose and number of immunizations required to elicit CTL responses to HPV epitopes
We examined the dose and number of immunizations required to evoke CTL responses by immunization with pE7HBE6 immunogen. When groups of mice were immunized with a range of doses of pE7HBE6, a single immunization with 10 mg, but not 1 mg, was sufficient to elicit RAH(E7)-directed IFN-g secretion and cytotoxicity against target cells presenting RAH(E7) peptide measurable in restimulated splenocytes (Figure 3a) .
We asked whether multiple immunizations would convert a sub-optimal dose (1 mg) to an effective dose, which elicited a response to an HPV epitope. Three immunizations with 1 mg were required to elicit RAH(E7)-directed IFN-g secretion and cytotoxicity against target cells presenting RAH(E7) peptide (Figure 3b) . We also measured the cytotoxic response to EVY(E6), ostensibly the 'weaker' of the two epitopes. Paradoxically, killing of EVY(E6) expressing targets tended to decrease the more immunizations given (Figure 3b ), although the differences were not significant.
Mutual interference of RAH(E7) and EVY(E6) CTL responses
We were concerned that to obtain maximum protective efficacy of pE7HBE6 vaccine against E7-and E6-expressing tumor, it might be necessary to generate substantive responses to both RAH(E7) and EVY(E6) epitopes. We noted in mice immunized with 100 mg of pE7HBE6 that the magnitude of IFN-g secretion and cytotoxic responses to EVY(E6) epitope was consistently less than that to RAH(E7) epitope (Figures 2a, c and e) . Surprisingly, however, we also noted that a single 1 mg dose of pE7HBE6, which was suboptimal for an RAH(E7) response, elicited a comparatively higher EVY(E6) response (Figure 3b) . However, the EVY(E6) response tended to decline, whereas the RAH(E7) response improved when multiple immunizations with 1 mg were administered (Figure 3b) .
To examine this discrepancy in response characteristics, we first determined the avidity of the T-cell response to EVY(E6) and RAH(E7) epitopes. We measured IFN-g secretion of ex vivo splenocytes from groups of mice immunized with one of two pE7HBE6 mutants in which either the RAH(E7) or the EVY(E6) epitope had been functionally 'knocked-out'( pE7 ko HBE6 and pE7HBE6 ko , respectively, Figure 5a and 'Materials and methods'). When splenocytes from mice immunized with the relevant mutant were stimulated with progressively reducing concentrations RAH(E7) or EVY(E6) or no peptide, significantly fewer cells secreted IFN-g in response to RAH(E7) epitope than to EVY(E6) epitope at the lower concentrations (0.250 and 125 mg ml -1 ) (Figure 4 ). These data suggest that the avidity of splenocytes bearing a T-cell receptor for EVY is higher than the avidity of splenocytes bearing the T-cell receptor for RAH in the context of major histocompatibility complex class I.
To analyze a putative interference between EVY(E6) and RAH(E7) responses, we used immunization with pE7 ko HBE6 to examine the EVY(E6) CTL response in the absence of an RAH(E7) response. Splenocytes from mice immunized with pE7 ko HBE6 contained significantly more EVY-specific IFN-g-secreting cells than mice immunized with pE7HBE6, which encodes an intact RAH(E7) epitope (ex vivo *Po0.0005, Figure 5b ; after restimulation *Po0.0005, Figure 5c ).
To examine the RAH(E7) response in the absence of an EVY(E6) response, we used immunization with pE7H-BE6 ko . Surprisingly, ex vivo splenocytes from mice immunized with pE7HBE6 ko contained significantly fewer RAH(E7)-specific IFN-g-secreting cells than mice immunized with pE7HBE6 (**Po0.0005 Figure 5b) .
These results suggested a puzzling relationship between RAH(E7) and EVY(E6) responses. We therefore analyzed whether, spatially separating RAH(E7) and EVY(E6) epitopes might change the responses after immunization. To do this, individual mice were immunized in separate ears with pE7 ko HBE6 and pE7HBE6 ko , and IFN-g secretion of splenocytes subsequently compared to those
of mice immunized with pE7HBE6. A higher number of splenocytes made an EVY-specific IFN-g response compared to splenocytes from pE7HBE6-immunized mice (ex vivo, ***Po0.0005, Figure 5b ; after restimulation, ***Po0.0005, Figure 5c ). Conversely, a lower number of splenocytes made a RAH(E7)-specific IFN-g response compared to splenocytes from mice immunized with pE7HBE6 (ex vivo, ****Po0.0005, Figure 5b ; after restimulation, ****Po0.0005, Figure 5c ). In summary, data derived from pE7HBE6 immunogen and its mutant derivatives indicate that (i) when immunizing with 100 mg of pE7HBE6, the RAH(E7) response is stronger than the EVY(E6) response ( Figure  2a , c and e) (ii) the ex vivo RAH(E7) response is stronger in the presence of an EVY(E6) response than in the absence of an EVY(E6) response (Figure 5b) , (iii) a single immunization with a low dose (1 mg) of pE7HBE6 elicits an EVY(E6) response but not a RAH(E7) response (Figure 3b ), (iv) after multiple immunizations with a low dose (1 mg), the EVY(E6) response tends to decline and a RAH(E7) response appears ( Figure 3b ) and (v) when RAH(E7) and EVY(E6) epitopes are physically separated, an upregulation of EVY(E6) responses, but a downregulation of RAH(E7) responses occurs (Figure 5c ). In effect, there appears to be a bidirectional association of magnitude of response between the two epitopes in the context of the E7HBE6 vaccine. Future studies in our laboratory will address the possible mechanism(s).
Immunization of mice with pE7HBE6 confers protection against growth of subcutaneous tumor-expressing HPV16 E7 and E6 antigens We analyzed whether immunization with pE7HBE6 would protect against the subcutaneous growth of a Prevention of growth of E7-and E6-expressing TC-1 tumor in E7-vaccinated mice is associated with a RAH(E7)-directed CTL response. 6, 14, 22 To determine whether tumor prevention was also associated with a major histocompatibility complex class I (EVY)E6-directed CTL response in our system, groups of mice were immunized twice with pE7 ko HBE6 (which elicits (EVY)E6-directed CTL, but is incapable of eliciting RAH(E7)-CTL; Figure 5 ) or with pHB w/t, and 14 days later injected with TC-1 tumor cells. pE7 ko HBE6-immunized mice were significantly protected against development of tumor compared to pHB w/t-immunized mice (*Po0.005 Figure 6b ).
To determine whether tumor prevention required a contribution from CD4 þ cells, mice were immunized with pE7HBE6, depleted of CD4 þ cells and then challenged with tumor ( Figure 6c) . Retention of the ability to make a RAH-directed CD8 þ IFN-g response was determined immediately before tumor cell challenge and was similar in non-depleted and depleted groups (Figure 6d) . A significantly larger number of mice, which were depleted of CD4 þ cells developed tumor compared to mice, which were not depleted of CD4 þ cells (*Po0.05 Figure 6e ). This result indicates a role for Figure 6b , that pHB w/t-immunized mice with an intact CD4 compartment, that is, nondepleted, were not protected against tumor, thus eliminating the interpretation that mice immunized with pE7 ko HBE6 were protected by a direct nonspecific CD4-mediated response). ko HBE6, or pHB w/t, or with 100 mg of peptide þ adjuvant, as indicated. To confirm efficacy of vaccination procedure, induction of RAH (E7)-and EVY(E6)-specific IFN-g-secreting splenocytes was shown wherein appropriate by ELISPOT assay 14 days later from splenocytes from two representative mice per group (not shown). (c and e) mice (n ¼ 10) were immunized twice i.d. at a 2-week interval with 100 mg pE7HBE6, then, commencing the following day (after ELISPOT confirmation of ex vivo RAH (E7)-and EVY(E6)-response in two representative mice per group), depleted of CD4 þ cells by administration of GK1.5 antibody (Materials and methods). CD4 depletion was confirmed by fluorescence-activated cell sorting (FACS) analysis of anti-CD4 stained splenocytes from GK1.5-treated and phosphate-buffered saline-treated mice (c). The retention of the capacity of splenocytes from depleted mice to make CD8 þ RAH-and EVY-epitope-specific IFN-g responses was confirmed by ELISPOT assay (d). The remaining mice in each group (n ¼ 4-7) were challenged with 2 Â 10 5 TC-1 tumor cells subcutaneously (s.c.) on the flank. Tumor growth was monitored to 76 days (b) or 50 days (e) as the percentage of mice with palpable tumor. (f, g) tumor therapy: mice (n ¼ 10) were injected s.c. with 5 Â 10 5 TC-1 cells. After 11 days, the mice were immunized i.d. five times at 3-day intervals with 100 mg pE7HBE6 or pHB w/t. Tumor growth was monitored as % survival (mice with tumors in excess of 1000 mm 3 were killed in accordance with animal ethics requirements), and by caliper measurement of individual tumors. Tumor incidence/survival was compared among groups using a log-rank statistic.
Hepatitis B surface antigen tumor vaccine O Haigh et al
To determine whether immunization with pE7HBE6 had a therapeutic effect on pre-existing tumor growing subcutaneously, mice were inoculated with TC-1 tumor, and were subsequently immunized commencing 11 days later when tumor growth was evident. Immunization with pE7HBE6 slowed the growth of tumor in terms of mouse survival (*Po0.005 Figure 6f) , and individual tumor growth (Figure 6g) .
Immunization of mice with pE7HBE6 prevents the establishment of tumor in lungs after systemic delivery of TC-1 cells A putative role of tumor immunotherapy is to prevent the growth of secondary tumors after systemic (hematological) spread. Entrapment of blood-borne tumor cells and their subsequent proliferation to form tumor nodules in the lungs of mice provides a model of metastatic tumor spread in humans. 13 We analyzed whether immunization would prevent the establishment of tumor growth in the lungs of mice previously inoculated with TC-1 tumor cells. Mice were injected intravenously with 10 5 TC-1 cells, a dose previously shown to result in lung tumors by 20-30 days after inoculation. 13 Groups of mice were immunized 3 and 10 days later with pE7HBE6, with a mix of pE7 ko HBE6 and pE7HBE6 ko , or with pHB w/t. Twenty-eight days after tumor inoculation, the mice were killed and lungs and spleens were removed. The lungs were examined histologically for the presence of tumor. No tumor growth was demonstrable in lungs of mice immunized with pE7HBE6 or with a mix of pE7 ko HBE6 and pE7HBE6 ko , whereas lungs of 80% of mice immunized with pHB w/t had massive tumor foci (Table 1 and Figure 7 ). In lungs sections in which tumors were detected, 1-3 separate tumor foci were distinguishable. We confirmed by ex vivo ELISPOT assay on splenocytes that mice immunized with pE7HBE6 or with a mix of pE7 ko HBE6 and pE7HBE6 ko , but not pHB w/t, showed (RAH)E7-and (EVY)E6-directed IFN-g-secreting CTL responses as in Figure 5b (data not shown) .
These data indicate that establishment of experimental E6-and E7-expressing tumor metastases in the lung was prevented by immunization with recombinant HBsAg DNA vaccines, and that this prevention correlated with vaccine-induced E7-and E6-directed CTL responses.
Together the tumor protection data indicate that immunization with rHBsAg DNA encoding HPV16 E7 and E6 oncoproteins has a prophylactic and therapeutic effect on the growth of E7-and E6-expressing tumor, which is associated with RAH(E7)-and EVY(E6)-CD8 þ CTL, and the presence of CD4 þ T cells contributes to the protective effect.
Discussion
In this study, we analyzed the efficacy of a novel recombinant HBsAg DNA vaccine, pE7HBE6, which expresses the E7 and E6 oncoproteins of HPV16, as N 0 -and C 0 -terminal extensions respectively of the HBsAg protein. The rHBsAg gene was human codon optimized for maximal expression and mutated to abrogate oncogenicity of the encoded oncoproteins. A single immunization with pE7HBE6 induced ex vivo effector and memory E6-and E7-directed CTL responses. Immunizationinduced responses were associated with long-lasting protection against the growth of E6-and E7-expressing tumor in the periphery, and against tumor development from malignant cells seeded systemically into the lungs. We have previously shown that vaccine-induced E7-directed CTL responses did not protect against non-E7-expressing tumor. 28 Cervical carcinoma, which is now recognized by the World Health Organization as being 100% attributable to HPV 29 causes ca 400 000 deaths per annum worldwide, and is the leading cause of cancer-related death in women in developing countries. HPV16 accounts for ca 60% of cervical carcinomas. While recently introduced prophylactic vaccines to prevent HPV infection are likely to decrease cervical cancer incidence, ca 5 million women are predicted to die during the 10-to 20-year period until the effect of the vaccine is felt. 30 In addition, religious, cultural and logistic considerations are likely to circumscribe population coverage of prophylactic vaccines. These issues warrant the development of therapeutic vaccine intervention for cervical cancer.
Uncontrolled expression of the HPV 16 E7 and E6 proteins transform basal keratinocytes of squamous epithelium of the cervix in a multi-step process, which requires the persistence of E7 and E6 oncoproteins for the cells to remains transformed. These proteins are thus ideal tumor-specific antigens to which immunotherapeutic strategies may be directed. Both animal models of HPVassociated tumor development, 6, 7, 22, 31 and human clinical trials of vaccines for cervical cancer 12, 30, 32 have exploited E7 and E6 as vaccine targets, the aim being to elicit major histocompatibility complex class I-restricted CTL responses to epitopes contained within these proteins. Approaches hitherto of immunizing with peptides or with whole proteins in a recombinant viral vector have produced disappointing results in clinical trials. [32] [33] [34] The approaches have been limited by the availability of suitable adjuvants predisposing to a Th1 response and licensed for use in humans, by regulatory issues surround- Table 1 Immunization with pE7HBE6 prevents the establishment in the lungs of tumors expressing HPV16 E6 and E7. H-2 b mice (five per group) were injected intravenously (tail vein) with 1 Â 10 5 TC-1 cells in 100 ml Hank's balance salt solution. The mice were subsequently immunized twice intradermally with 100 mg pE7HBE6, with a mix of 50 mg each of pE7HBE6 ko plus pE7 ko HBE6, or with pHB w/t, 3 and 10 days later. Lungs were excised 18 days after the second immunization, sectioned and stained with hematoxylin and eosin, and tumor incidence evaluated microscopically ing live vectors, and by pre-existing immunity to vector abrogating HPV-directed responses. Therapeutic vaccination is not a recognized treatment modality in any cancer, in spite of many attempts at cancer immunotherapy having been conducted (reviewed in Cavallo et al. 35 ). Clearly, the mode of vaccination is of paramount importance in achieving therapeutic outcomes for established neoplastic disease. Although preventative vaccines are based on induction of neutralizing antibodies, therapeutic vaccines, by contrast, require effective induction of cell-mediated immunity. A therapeutic vaccine for cervical cancer requires a powerful antigen delivery system. Further essential elements of a good vaccine include safety, low-cost manufacture, storage and administration. HBsAg is the already-licensed human vaccine for hepatitis B infection, with a safety and efficacy record in tens of millions of individuals. HBsAg DNA vaccine is easily produced and is very potent at inducing CTL responses. 21 It is, therefore, an extremely attractive vector for the delivery of tumor-associated antigens, which may overcome shortcomings of current approaches to cervical cancer immunotherapy.
Cancer deaths frequently relate to metastases for which conventional therapies such as surgery, chemotherapy and radiotherapy have limited success. Immunotherapy is an attractive alternative for treatment of metastatic disease because of its tumor specificity, and its potential capacity to eliminate tumors at multiple sites in the body. After the draining lymph nodes, the lungs are among the most common sites of distant metastases of cervical carcinoma. 36 It is thus particularly relevant that the recombinant HBsAg vaccines we describe were able to prevent hematological spread to the lungs of a tumor (TC-1) of epithelial origin expressing E7-and E6-oncoproteins.
As a result of the intrinsic capacity of HBsAg to form highly immunogenic VLPs, it has attracted further attention as a potential vector for the delivery of tumor epitopes. 19, 37 Comparison of delivery of HBsAg as a DNA vaccine with it's delivery as a VLP vaccine, suggests that the former is the preferred modality for the induction of CTL-mediated immunity in terms of immunogenic efficacy, and economically and practically. 37 Progress in DNA vaccination in humans has been slowed by the large amounts of DNA required to elicit physiologically relevant immune responses. However, HBsAg DNA vaccination requires a dose up to 2500-fold lower in humans than used in previous clinical trials with conventional DNA. 18 It remains unclear whether this startling efficacy requires the formation of HBsAg VLPs in vivo, or whether it may be accounted for by epitope concentration, the intrinsic provision of T-help 38 and the immunostimulatory capacity of HBsAg protein aggregates. On-going transcription from persisting HBsAg DNA (for example, in muscle cells 39 and follicular dendritic cells 40 leading to continuous exposure to small doses of antigen 39, 41 ) is likely responsible for the persistence of effector and memory CTL responses for many months in mice after a single injection of HBsAg plasmid DNA. 42 Transfected antigen-presenting cells Hepatitis B surface antigen tumor vaccine O Haigh et al will activate the CTL response through the intracellular (endogenous) processing pathway, 20 after injection of DNA vaccine. That we were unable to detect E7HBE6 protein in mammalian cells after direct in vitro transfection (data not shown), might suggest rapid degradation, which is consistent with enhanced antigen processing. 43 The capacity of rHBsAg DNA vaccines to elicit powerful CTL responses is undiminished in the presence of HBsAg antibody (D Chen, submitted) further arguing for a DNA approach in which rHBsAg DNA vaccine may be given to recipients who sustain an HBsAg B-memory response from previous vaccination with HBsAg VLPs for hepatitis B virus infection.
A synergistic effect of E7-directed and E6-directed CTL responses in the control of tumor, greater than either entity alone has previously been shown. 13 Our studies confirm that E6 contributes to tumor protection (Figure 6b) . Thus, the observed discrepancy between the magnitudes of RAH(E7) and EVY(E6) responses when immunizing with pE7HBE6, depending on dose and number of immunizations (Figure 3 ), is therefore of some concern in this context. It likely reflects immunodominance (avidity) issues involving RAH(E7) and EVY(E6). Our finding (Figure 4 ) on the relative avidities of the two epitopes carries the caveat that the RAH(E7) peptide we used is longer than the minimal epitope (see 'Materials and methods'). However, RAH(E7) loads H-2D b molecules as measured by functional assay as efficiently as the minimal epitope 31 and Tindle (pers. obs.). An immunodominance effect may also be mediated by CTL epitopes within the HBsAg carrier 19 particularly if any of these elicit CTL of high avidity.
Separating the RAH(E7) and EVY(E6) responses in space using epitope 'knock out' mutants tended to resolve differences in the magnitude of the RAH(E7) and EVY(E6) responses although at the price of a lowering of the RAH(E7) response ( Figure 5 ). Separating the RAH(E7) and EVY(E6) responses in time was not effective: Thus, two immunizations with pE7 ko HBE6 elicited EVY-specific CTL detectable ex vivo, but subsequent immunization with pE7HBE6 ko or pE7HBE6 2 weeks later, failed to elicit RAH-specific CTL (data not shown). This latter observation is likely due to 'original antigenic sin' of the carrier (HBsAg) CTL epitopes 44 incurred by the first immunization, preventing response to the later immunization. This concept is particularly relevant for vectored vaccines, and underscores the importance of our observation of the efficacy of pE7HBE6 after a single immunization. In any case, the practice of repeated immunizations with high-dose antigen conducted with the aim of achieving maximum immunogenicity may be misguided, because of the putative generation of antigen-specific T cells, which become exhausted through loss of replicative capacity and apoptotic depletion. 45, 46 We observed that CD4 cell depletion of pE7HBE6-immunized mice before tumor challenge increased the proportion of mice, which acquired tumor (Figure 6c ). CD4-mediated T-help in the induction phase of CTLmediated tumor regression is often required. CD4 depletion has been observed to lead to abrogation of tumor protection is some experimental systems, 8, 47 more than others. 31 This likely reflects the immunization regimen, the tumor used for challenge, and the relative strength of the antigen ('strong' epitopes endowing the capacity of antigen-specific CTLs to secrete their own interleukin-2, that is, 'help' 48, 49 ). Our studies show the feasibility of HBsAg as a powerful genetic vector to deliver CTL responses to co-encoded tumor antigens. Our results have specific implications for the development of a HBsAg-vectored therapeutic DNA vaccine for HPV-associated squamous carcinoma targeting HLA-restricted epitopes of HPV16 E6 and E7. 50 
